Ecacy of Oral SERDs in the treatment of ER+, HER2 - metastatic breast cancer, a stratied analysis of the ESR1 wild type and mutant subgroups
Dynamics and type of ESR1 mutations under aromatase inhibitor or fulvestrant combined with palbociclib after randomization in the PADA-1 trial
Key Abstracts/Publication in ER+ve Breast Cancer
Chairpersons :
Dr. Ranga Rao, Dr. Sudha Sinha
Speaker :
Dr. Mansi Sharma